Immunitybio Inc
$ 7.78
2.37%
15 Apr - close price
- Market Cap 7,538,842,000 USD
- Current Price $ 7.78
- High / Low $ 7.80 / 7.36
- Stock P/E N/A
- Book Value -0.50
- EPS -0.38
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.36 %
- ROE N/A %
- 52 Week High 12.43
- 52 Week Low 1.83
About
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Analyst Target Price
$14.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-03-17 | 2024-11-06 | 2024-08-06 | 2024-05-09 | 2024-03-19 | 2023-11-09 | 2023-08-08 | 2023-05-11 |
| Reported EPS | -0.06 | -0.07 | -0.1 | -0.15 | -0.08 | -0.1232 | -0.2 | -0.2 | -0.35 | -0.19 | -0.32 | -0.27 |
| Estimated EPS | -0.1106 | -0.11 | -0.11 | -0.16 | -0.13 | -0.18 | -0.17 | -0.16 | -0.18 | -0.25 | -0.23 | -0.27 |
| Surprise | 0.0506 | 0.04 | 0.01 | 0.01 | 0.05 | 0.0568 | -0.03 | -0.04 | -0.17 | 0.06 | -0.09 | 0 |
| Surprise Percentage | 45.7505% | 36.3636% | 9.0909% | 6.25% | 38.4615% | 31.5556% | -17.6471% | -25% | -94.4444% | 24% | -39.1304% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IBRX
2026-04-16 02:10:30
Robbins LLP is urging stockholders of ImmunityBio, Inc. (NASDAQ: IBRX) who incurred losses to contact the firm regarding a class action lawsuit. The lawsuit alleges that ImmunityBio misled investors about its lead product, Anktiva, after a warning letter from the U.S. Food and Drug Administration publicized materially overstated claims made by defendant Soon-Shiong concerning the product's capabilities. ImmunityBio's stock subsequently fell by 21% following this news.
2026-04-16 00:10:30
Kirby McInerney LLP is reminding ImmunityBio, Inc. investors with significant losses that the deadline to seek the role of lead plaintiff in a federal securities class action is May 26, 2026. The lawsuit alleges that the Company's Executive Chairman, Patrick Soon-Shiong, materially overstated the capabilities of Anktivas, leading to a significant stock price decline after a warning letter from the FDA regarding misleading promotional materials. Investors who purchased ImmunityBio securities during the Class Period of January 19, 2026, through March 24, 2026, are encouraged to contact the law firm.
2026-04-15 19:10:31
Hagens Berman has announced an investor class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit stems from a warning letter issued by the FDA regarding misleading efficacy claims made by ImmunityBio's executive chairman about their lead biologic product, Anktiva, which caused the stock to drop over 21%. Investors with substantial losses are urged to contact Hagens Berman to participate in the investigation.
2026-04-15 16:41:37
Glancy Prongay Wolke & Rotter LLP reminds investors of ImmunityBio, Inc. (IBRX) about the May 26, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. This lawsuit stems from an FDA Warning Letter, which indicated that ImmunityBio’s Executive Chairman made inaccurate claims about its product, Anktiva, leading to a significant drop in stock price. The complaint alleges that the company's positive statements were materially misleading due to the overstatement of Anktiva’s capabilities.
2026-04-15 16:09:38
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ImmunityBio, Inc. and its officers for alleged federal securities law violations. The lawsuit claims that CEO Soon-Shion materially overstated the capabilities of Anktiva, leading to false and misleading statements about the company's business and prospects. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are encouraged to join the case, with a lead plaintiff deadline of May 26, 2026.
2026-04-15 15:09:37
ImmunityBio, Inc. is being sued in a class action lawsuit by Berger Montague PC on behalf of investors who purchased shares between January 19, 2026, and March 24, 2026. The lawsuit alleges that the company's Chief Scientific and Medical Officer overstated the capabilities of its Anktiva platform, leading to misleading statements about the company's prospects. Investors have until May 26, 2026, to seek lead plaintiff representation.
